Rifampicin and Parkinson’s disease

Mitochondrial Dysfunction in Parkinson's Disease

(2017) Jianhui Zhu et al.   JOURNAL OF ALZHEIMERS DISEASE

Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease

(2012) Li Lu et al.   CNS & Neurological Disorders-Drug Targets

Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation

(2011) Wei Bi et al.   BRAIN RESEARCH

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

(2011) Karin Wirdefeldt et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Priorities in Parkinson's disease research

(2011) Wassilios G. Meissner et al.   NATURE REVIEWS DRUG DISCOVERY

The Role of Mitochondria in Reactive Oxygen Species Metabolism and Signaling

(2010) Anatoly A. Starkov   Annals of the New York Academy of Sciences

Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy

(2010) Li Qian et al.   JOURNAL OF NEURAL TRANSMISSION

Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-κB DNA-binding Activity in RAW 264.7 Cells

(2010) Seong Keun Kim et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein

(2009) Vladimir Uversky et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders

(2008) Kenjiro Ono et al.   CURRENT PHARMACEUTICAL DESIGN

The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery

(2008) Garima Dutta et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Practice Pearl: A Novel Use of Rifampicin for Treatment of Carpal Tunnel Syndrome

(2008) Hamid Namazi   JOURNAL OF PAIN